Key result
Thrombolytic therapy for acute myocardial infarction caused a significant rebound increase in PAI-1 approximately 3 hours after cessation, independent of the plasminogen activator used.
Why the study?
Does the type of thrombolytic agent affect the rebound increase of PAI-1 after cessation of therapy in patients with acute myocardial infarction?
Observational (n=50)
Does the type of thrombolytic agent affect the rebound increase of PAI-1 after cessation of therapy in patients with acute myocardial infarction?
A marked, drug-independent rebound increase in PAI-1 occurs after cessation of thrombolytic therapy for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
May heighten post-MI reocclusion risk after thrombolysis; leaves open whether adjunctive strategies mitigate the drug-independent rebound.
Plasma concentrations of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1), and D-dimer were investigated in 50 patients treated intravenously for acute myocardial infarction with either streptokinase (n = 23), urokinase (n = 17), or recombinant t-PA (rt-PA, n = 10). The fibrinolytic variables were measured by enzyme immunoassay on admission; 1, 2, 4, 6, 8, 12, and 24 h later; and then daily until day 7 after admission. In each subgroup of patients treated with different thrombolytic agents, PAI-1 increased significantly (P < 0.01) approximately 3 h after cessation of thrombolytic therapy. PAI-1 peak concentrations did not differ significantly (P = 0.82) among these three subgroups. t-PA and D-dimer did not differ significantly (P > 0.14) among subgroups except for higher t-PA in the rt-PA group attributable to detection of the therapeutically administered exogenous rt-PA by the t-PA assay. Our findings demonstrate a marked PAI-1 increase after thrombolytic therapy for acute myocardial infarction, which seems to be a common, drug-independent antifibrinolytic rebound phenomenon in response to thrombolytic treatment.
No takes yet. Share an insight, caveat, or question.
Genser et al. (1998) conducted an observational in acute myocardial infarction (n=50). Thrombolytic treatment (streptokinase, urokinase, or rt-PA) vs. Comparison among different thrombolytic agents was evaluated on Plasma concentrations of PAI-1, t-PA, and D-dimer (p=<0.01). Thrombolytic therapy for acute myocardial infarction caused a significant rebound increase in PAI-1 approximately 3 hours after cessation, independent of the plasminogen activator used.
Synapse has enriched 10 related papers. Consider them for comparative context: